@article{63e8cd696a2e446e98d91b98f3ac9b8f,
title = "Migraine and epilepsy: Progress towards preemptive therapy",
author = "Haut, {Sheryl R.} and Lipton, {Richard B.}",
note = "Funding Information: Dr. Sheryl R. Haut receives grant support from NIH ( RO1NS053998 ) and the Shor Foundation for Epilepsy Research . She has consulted for Acorda, Vivus, Neuronex, and Upsher-Smith. She is on the editorial board of Epilepsy & Behavior and Epilepsy Currents. Dr. Richard B. Lipton receives research support from NIH [ PO1AG03949 (Program Director), PO1AG027734 (Project Leader), RO1AG025119 (Investigator), RO1AG022374-06A2 (Investigator), RO1AG034119 (Investigator), RO1AG12101 (Investigator), K23AG030857 (Mentor), K23NS05140901A1 (Mentor), and K23NS47256 (Mentor)], the National Headache Foundation , and the Migraine Research Fund . He serves on the editorial boards of Neurology and Cephalalgia and as a senior advisor to Headache; has reviewed for the NIA and NINDS; holds stock options in eNeura Therapeutics (a company without commercial products); and serves as consultant, advisory board member, or has received honoraria from Allergan, American Headache Society, Autonomic Technologies, Boehringer-Ingelheim Pharmaceuticals, Boston Scientific, Bristol-Myers Squibb, CogniMed, CoLucid, Eli Lilly, ENDO, eNeura Therapeutics, GlaxoSmithKline, MAP, Merck, Nautilus Neuroscience, Novartis, NuPathe, Pfizer, and Vedanta. ",
year = "2013",
month = aug,
doi = "10.1016/j.yebeh.2013.04.018",
language = "English (US)",
volume = "28",
pages = "241--242",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",
number = "2",
}